Genmab A/S (NASDAQ:GMAB) Shares Sold by Ingalls & Snyder LLC

Ingalls & Snyder LLC lessened its position in shares of Genmab A/S (NASDAQ:GMAB - Free Report) by 37.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 136,059 shares of the company's stock after selling 82,424 shares during the period. Ingalls & Snyder LLC's holdings in Genmab A/S were worth $2,840,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in GMAB. Legacy Wealth Asset Management LLC boosted its position in Genmab A/S by 1.1% during the third quarter. Legacy Wealth Asset Management LLC now owns 44,979 shares of the company's stock valued at $1,097,000 after acquiring an additional 471 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its position in Genmab A/S by 10.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,891 shares of the company's stock worth $186,000 after buying an additional 827 shares in the last quarter. GAMMA Investing LLC raised its position in Genmab A/S by 96.6% during the fourth quarter. GAMMA Investing LLC now owns 2,139 shares of the company's stock valued at $45,000 after purchasing an additional 1,051 shares in the last quarter. Eagle Asset Management Inc. grew its holdings in shares of Genmab A/S by 10.0% during the 3rd quarter. Eagle Asset Management Inc. now owns 12,356 shares of the company's stock valued at $285,000 after purchasing an additional 1,121 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC boosted its holdings in Genmab A/S by 43.6% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 4,653 shares of the company's stock valued at $113,000 after acquiring an additional 1,413 shares during the period. Institutional investors and hedge funds own 7.07% of the company's stock.

Genmab A/S Trading Up 1.8 %

NASDAQ GMAB traded up $0.38 on Friday, hitting $21.30. 2,417,574 shares of the company traded hands, compared to its average volume of 1,682,134. The company has a market capitalization of $14.10 billion, a price-to-earnings ratio of 20.68, a P/E/G ratio of 0.54 and a beta of 0.96. The business's 50 day moving average price is $20.65 and its 200-day moving average price is $23.11. Genmab A/S has a 52-week low of $18.64 and a 52-week high of $31.88.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last posted its quarterly earnings results on Wednesday, February 12th. The company reported $0.57 EPS for the quarter, beating analysts' consensus estimates of $0.28 by $0.29. Genmab A/S had a return on equity of 14.64% and a net margin of 23.49%. As a group, sell-side analysts predict that Genmab A/S will post 1.25 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts have commented on the company. BNP Paribas raised Genmab A/S from a "strong sell" rating to a "hold" rating in a research report on Tuesday, February 11th. Sanford C. Bernstein raised Genmab A/S from a "strong sell" rating to a "hold" rating in a research report on Friday, December 20th. BMO Capital Markets reiterated an "outperform" rating and set a $48.00 target price (up from $46.00) on shares of Genmab A/S in a research note on Friday, November 8th. Leerink Partners upgraded Genmab A/S from a "market perform" rating to an "outperform" rating and set a $27.00 target price on the stock in a research note on Thursday. Finally, HC Wainwright reiterated a "buy" rating and set a $50.00 target price on shares of Genmab A/S in a research note on Thursday, January 23rd. Four investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Genmab A/S currently has an average rating of "Moderate Buy" and a consensus target price of $42.17.

Genmab A/S Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.